At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
GlucaGendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
In Brief
A clinical study evaluating GlucaGen for Type 1 Diabetes and Hypoglycemia. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The primary aim of the study is to evaluate the glucose response to low-dose glucagon (single 150 µg dose) administered immediately before aerobic exercise in individuals with AHCL-treated T1D.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Hypoglycemia
CountriesDenmark
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartSep 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedMay 18, 2022
Enrollment StartSep 21, 2022
Primary CompletionMay 13, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.1 years ago
Interventions
GlucaGendrug
150 ug glucagon will be administered to the participants before exercise.